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Introduction: Gastrin-releasing peptide receptors (GRPr) are expressed in high 
numbers on human prostate cancer.  The bombesin peptide derivative, BBN(7-
14)NH2, has high affinity and selectivity to GRPr.  Therefore, Copper-64 (64Cu) 
radiolabeled bombesin conjugates could have potential in positron-emission 
tomography (PET) of human prostate cancer.   
 
Methods: In vitro assays of the NO2A bombesin conjugates and non-radioactive 
63Cu-NO2A bombesin conjugates were performed in human PC-3 cells.  In vivo 
pharmacokinetic studies of the radiolabeled 64Cu-NO2A bombesin conjugates were 
performed in normal CF-1 and PC-3 tumor-bearing SCID mice.  In vivo, multimodal, 
molecular images were obtained of the radiolabeled 64Cu-NO2A bombesin conjugates 
in PC-3 tumor-bearing SCID mice via microPET/CT. 
 
Results: In vitro studies indicated idea uptake of the NO2A bombesin conjugates 
(1.99-6.24 nM), and 63Cu-NO2A bombesin conjugates (3.16-51.81 nM) in PC-3 cells.  
In vivo results of the 64Cu-NO2A bombesin conjugates at 1, 4, and 24 h p.i. showed 
affinity towards GRPr-positive tissue and effective clearance properties.  Due to the 
favorable in vivo pharmacokinetic properties of 64Cu-NO2A bombesin conjugates, 
high-resolution multimodal, molecular imaging was performed via microPET/CT in a 
PC-3 tumor-bearing SCID mouse model.  High-quality target to non-target images 
were obtained, with the tumors clearly visible.   
 
Conclusions: The 64Cu-NO2A bombesin conjugates showed affinity and specificity 
towards GRPr-positive tissues.  High quality microPET images of PC-3 xenografted 
tumors in SCID mouse model were obtained, demonstrating the potential for PET 
imaging of GRPr-positive human prostate cancer tumors. 
 
